The 15,000-square-foot facility operates a producing line designed to provide 500-600 kg of lively pharmaceutical components (API) yearly. It integrates discovery, course of improvement, and cGMP manufacturing for extremely potent molecules, together with cytotoxic payloads utilized in oncology, to minimise handoffs throughout the event journey, in response to a press release on Wednesday.
The platform, Aragen OneHP, is designed to deal with compounds at occupational publicity limits of as much as 10 ng/m³ and lays the groundwork for enlargement into superior modalities, reminiscent of antibody-drug conjugates and peptide-drug conjugates.
Additionally learn: Centre might search authorized view on licensing of sterile medicine
Aniel Khubchandani, Chief Govt Officer, Small Molecules-CDMO, Aragen stated, “With OneHP, we’re bringing discovery, improvement and cGMP manufacturing for extremely potent molecules onto a extra built-in platform. This will cut back handoffs between suppliers, whereas retaining course of information and programme context related as a molecule strikes from early improvement in the direction of industrial provide.
The corporate said that it invested over Rs 1,000 crore in capital expenditure over the three years resulting in March 2026. Its contract improvement and manufacturing phase registered a 19 per cent compound annual progress price throughout this timeframe, with put in small-molecule capability reaching 364 KL throughout its Hyderabad and Visakhapatnam websites.
